Expand ARQT Menu
ARQT MENU

ARQT Latest Press Releases

-- December 8, 2025 --

Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri Globe Newswire 4:00 PM

-- November 17, 2025 --

FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 Globe Newswire 8:00 AM

-- November 13, 2025 --

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis Globe Newswire 8:00 AM

-- November 7, 2025 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- November 4, 2025 --

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology Globe Newswire 8:00 AM

-- October 30, 2025 --

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments Globe Newswire 9:15 AM
Arcutis Launches ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 Globe Newswire 8:00 AM

-- October 28, 2025 --

Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results Globe Newswire 8:30 AM

-- October 27, 2025 --

Arcutis to Present at Upcoming Investor Conferences Globe Newswire 4:00 PM

-- October 24, 2025 --

Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference Globe Newswire 8:00 AM

-- October 6, 2025 --

FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 Globe Newswire 8:00 AM

-- October 3, 2025 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- September 29, 2025 --

Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 Globe Newswire 4:00 PM

-- September 17, 2025 --

Arcutis To Present Multiple New ZORYVE (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress Globe Newswire 4:00 AM

-- September 16, 2025 --

Allure Magazine Honors Arcutis' ZORYVE (roflumilast) with Prestigious Best of Beauty Breakthrough Award Globe Newswire 9:00 AM

-- September 5, 2025 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- September 3, 2025 --

Arcutis Submits Supplemental New Drug Application for ZORYVE (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5 Globe Newswire 11:43 AM
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer Globe Newswire 7:30 AM

-- August 19, 2025 --

Arcutis to Present at Upcoming Investor Conferences Globe Newswire 4:00 PM

-- August 8, 2025 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- August 6, 2025 --

Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update Globe Newswire 4:00 PM

-- July 31, 2025 --

Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund Business Wire 7:00 AM

-- July 23, 2025 --

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 Globe Newswire 4:00 PM
Market Data Delayed 15 Minutes